Literature DB >> 2306000

Hyperbaric oxygen therapy in chronic vascular wound management.

F Wattel1, D Mathieu, J M Coget, V Billard.   

Abstract

Many nonhealing tissues are hypoxic, with oxygen tensions frequently ranging from 5 to 15 mmHg. In such an environment, the normal wound healing sequence is disrupted or halted and phagocytic killing activity depressed. So the adjunctive use of hyperbaric oxygen (HBO), based on physiologic data and clinical observations, can provide the substrate necessary to initiate and sustain the healing process. During a twelve-month period, 20 patients with a nonhealing wound were referred to the hyperbaric center: chronic arterial insufficiency ulcers in 9 cases, diabetic wounds (foot lesions) in 11 cases. Adjunctive HBO therapy, initiated twice a day, consisted of pure oxygen, 2.5 ATA, 90 min. The average length of sessions was 46 (15-108). Complete healing was observed in 15 of 20 cases. The wound management can be helped with the transcutaneous oxygen measurements under hyperbaric oxygen. The distal TCPO2 at 2.5 ATA pure oxygen is a reliable test to predict final outcome (healing or no change), when these values were not different in normal air and in normobaric oxygen: (table; see text) In hyperbaric oxygen therapy, when the distal TCPO2 value was inferior to 100 mmHg, all patients showed either no improvement or aggravation, and when the value was higher than 100 mmHg, wound healing was achieved with all patients.

Entities:  

Mesh:

Year:  1990        PMID: 2306000     DOI: 10.1177/000331979004100109

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  12 in total

Review 1.  "It Takes a Village": Mechanisms Underlying Antimicrobial Recalcitrance of Polymicrobial Biofilms.

Authors:  Giulia Orazi; George A O'Toole
Journal:  J Bacteriol       Date:  2019-12-06       Impact factor: 3.490

2.  Hyperbaric oxygenation therapy for cyclophosphamide-induced haemorrhagic cystitis.

Authors:  H Yazawa; T Nakada; I Sasagawa; M Miura; Y Kubota
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

3.  [Treatment options of acral ulcers in MCTD].

Authors:  Ann-Kristin Herink; Lars Köthe; Matthias Girndt; Gernot Keysser
Journal:  Med Klin (Munich)       Date:  2010-12-07

Review 4.  What is the role of hyperbaric oxygen in the management of diabetic foot disease?

Authors:  Magnus Löndahl; Katarina Fagher; Per Katzman
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

5.  Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells.

Authors:  J E Kalns; E H Piepmeier
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-02       Impact factor: 2.416

6.  Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle-brachial index in patients with diabetes and chronic foot ulcers.

Authors:  M Löndahl; P Katzman; C Hammarlund; A Nilsson; M Landin-Olsson
Journal:  Diabetologia       Date:  2010-10-19       Impact factor: 10.122

Review 7.  The Diabetic Foot: A Historical Overview and Gaps in Current Treatment.

Authors:  Caroline C L M Naves
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-05-01       Impact factor: 4.730

8.  Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds.

Authors:  Gayle M Gordillo; Sashwati Roy; Savita Khanna; Richard Schlanger; Sorabh Khandelwal; Gary Phillips; Chandan K Sen
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-04-21       Impact factor: 2.557

Review 9.  Wound healing essentials: let there be oxygen.

Authors:  Chandan K Sen
Journal:  Wound Repair Regen       Date:  2009 Jan-Feb       Impact factor: 3.617

10.  Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis.

Authors:  Ozlen Atug; Hulya Hamzaoglu; Veysel Tahan; Inci Alican; Ozlem Kurtkaya; Emin Elbuken; Osman Ozdogan; Nurdan Tozun
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.